Login
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc.

trevitherapeutics.com

What Do They Do?

Develops Haduvio, an investigational oral therapy for chronic cough in people with idiopathic pulmonary fibrosis, other interstitial lung disease, and refractory chronic cough.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −82% (Loss)
vs −$11.8M in Q3 FY2025

Program focus The earlier report also described Haduvio development for prurigo nodularis; the latest describes Haduvio development for chronic cough in IPF, non-IPF ILD, and refractory chronic cough.

Who Do They Compete With?

Competes with Boehringer Ingelheim, GSK, Merck &, and Nocion Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support